Biblio

Author Title Type [ Year

]

Filters: Author is Wu, Depei [Clear All Filters]

2024

Gao L, Yang L, Zhou S, Zhu W, Han Y, Chen S, Xue S, Wang Y, Qiu H, Wu D, et al. Allogenic hematopoietic stem cell transplantation outcomes of patients aged ≥ 55 years with acute myeloid leukemia or myelodysplastic syndromes in China: a retrospective study. Stem Cell Res Ther. 2024;15(1):24.

Shen Y, Liu M, Shen D, Chu M, Li X, Zhang X, Fan Y, Chen J, Wu D, Hu S, et al. Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia: a large-scale propensity score matching-based study. Bone Marrow Transplant. 2024.

Zhou M, Chen Y, Gong Y, Zhu M, Cen J, Pan J, Yan L, Shang J, Jin S, Shi X, et al. Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma. Discov Oncol. 2024;15(1):78.

Zhou B, Chen J, Liu T, Ye Y, Zhang Y, Ding Y, Liu H, Zhu M, Ma X, Li X, et al. Haploidentical hematopoietic cell transplantation with or without an unrelated cord blood unit for adult acute myeloid leukemia: a multicenter, randomized, open-label, phase 3 trial. Signal Transduct Target Ther. 2024;9(1):108.

Beksac M, Eikema D-J, Koster L, Hulin C, Poire X, Hamladji R-M, Gromek T, Bazarbachi A, Ozkurt ZNur, Pabst T, et al. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2024.

Wu X, Ma X, Song T, Liu J, Sun Y, Wu D. The indirect effects of CMV reactivation on patients following allogeneic hematopoietic stem cell transplantation: an evidence mapping. Ann Hematol. 2024.

Zhang Z, Yin J, Lian G, Bao X, Hu M, Liu Z, Yu Y, Mi R, Zuo Y, Shi P, et al. A multi-center retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML. Blood Adv. 2024.

Cong M, Ai S, Kang L, Jin M, Zhu Y, Li C, Jin Z, Yu L, Wu D, Huang H. Outcomes of allogeneic hematopoietic stem cell transplantation in R/R DLBCL patients with failure of CAR-T therapy. Exp Hematol Oncol. 2024;13(1):4.

Wei X, Zhu W, Li J, Zhou S, Zhu Q, Ma X, Han Y, Wang Y, Miao M, Qiu H, et al. The role of pre-existing anti-HLA antibodies in severe aplastic anemia patients undergoing allogenic hematopoietic stem cell transplantation. Transplant Cell Ther. 2024.

2023

Lin Z, Wu Y, Zhao Y, Wang T, Xia J, Qiu H, Jin Z, Wu D, Chen F. Acute liver failure associated with human adenovirus infection after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2023.

Chen Y, Xu Y, Wu D. Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting. Exp Hematol Oncol. 2023;12(1):59.

Berning P, Schmitz N, Ngoya M, Finel H, Boumendil A, Wang F, Huang X-J, Hermine O, Philippe L, Couronné L, et al. Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis. Leukemia. 2023.

Chen J, Labopin M, Pabst T, Zhang X, Jiang E, Tucci A, Cornelissen J, Meijer E, Khevelidze I, Polge E, et al. Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the global co. Bone Marrow Transplant. 2023.

Li S, Ge J, Zhou S, Zhu W, Han Y, Chen S, Xue S, Wang Y, Qiu H, Wu X, et al. CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B-cell acute lymphoblastic leukaemia delays platelet recovery and increases risks of cytomegalovirus and Epstein-Barr vir. Clin Transl Med. 2023;13(10):e1459.

Xu X, Wang H, Han H, Yao Y, Li X, Qi J, Cai C, Zhou M, Tang Y, Pan T, et al. Clinical characteristics and prognostic significance of DNA methylation regulatory gene mutations in acute myeloid leukemia. Clin Epigenetics. 2023;15(1):54.

Yu Z, Yao Y, Zhang Y, Chen J, Xu Y, Xue S, Qiu H, Tang X, Han Y, Chen S, et al. The efficacy of first salvage therapy determines the outcomes of adult patients with type 1 primary refractory acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2023.

Ding Y, Liu C, Cai Y, Hou C, Chen G, Xu Y, Hu S, Wu D. The efficiency of human umbilical cord mesenchymal stem cells as a salvage treatment for steroid-refractory acute graft-versus-host disease. Clin Exp Med. 2023.

Devillier R, Eikema D-J, Dufour C, Aljurf M, Wu D, Maschan A, Kulagin A, Halkes CJM, Collin M, Snowden J, et al. Graft-versus-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT. Haematologica. 2023.

Zeng M, Xia J, Zong Z, Shi Y, Ni Y, Hu F, Chen Y, Zhuo C, Hu B, Lv X, et al. Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli. J Microbiol Immunol Infect. 2023.

Wei X, Chang Y, Zhu X, Hu X, Guo R, Zhang Y, Ma X, Han Y, Wang Y, Qiu H, et al. The impact of pre-transplant anti-HLA antibodies in transplants from HLA-identical sibling donors: A multicenter study. HLA. 2023.

Wu Q, Chen X, Qiao C, Cao X, Du Q, Yuan Y, Zuo Y, Miao Y, Zheng Z, Zhang T, et al. Methotrexate and Triptolide regulate Notch signaling pathway by targeting the Nedd4-Numb axis. Int Immunopharmacol. 2023;114:109595.

Yu Z, Yao Y, Zhang Y, Chen J, Xu Y, Xue S, Qiu H, Tang X, Han Y, Chen S, et al. Outcomes of adult patients with type 1 primary refractory acute myeloid leukemia: a single center experience. Hematology. 2023;28(1):2212534.

Chen Y, Huang X, Qiu H, Cheng L, Yu Y, Ma X, Feng S, Li Q, Wu D, Huang W, et al. Physicians' knowledge of invasive fungal disease in China. Mycoses. 2023.

Lai X, Xiao J, Wang T, Hou C, Chen J, Wu D, Xu Y. Prognostic significance of persisting DNMT3A, ASXL1, and TET2 mutation burden in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation during complete remission. Leuk Lymphoma. 2023:1-9.

Xiao J, Xie J, Zhou B, Liu Y, Lu J, Jiang A, Yao H, Qiu Q, Ding Z, Xue S, et al. RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia. Leuk Lymphoma. 2023:1-11.

Pages